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Abstract
Background: The clinical effects of mucolytics in patients with chronic obstructive pulmonary
disease (COPD) are discussed controversially. Cineole is the main constituent of eucalyptus oil and
mainly used in inflammatory airway diseases as a mucolytic agent. We hypothesised that its known
mucolytic, bronchodilating and anti-inflammatory effects as concomitant therapy would reduce the
exacerbation rate and show benefits on pulmonary function tests as well as quality of life in patients
with COPD.
Methods: In this double-blind, placebo-controlled multi-center-study we randomly assigned 242
patients with stable COPD to receive 200 mg of cineole or placebo 3 times daily as concomitant
therapy for 6 months during winter-time. The frequency, duration and severity of exacerbations
were combined as primary outcome measures for testing as multiple criteria. Secondary outcome
measures included changes of lung function, respiratory symptoms and quality of life as well as the
single parameters of the exacerbations.
Results: Baseline demographics, lung function and standard medication of both groups were
comparable. During the treatment period of 6 months the multiple criteria frequency, severity and
duration of exacerbations were significantly lower in the group treated with cineole in comparison
to placebo. Secondary outcome measures validated these findings. Improvement of lung function,
dyspnea and quality of life as multiple criteria were statistically significant relative to placebo.
Adverse events were comparable in both groups.
Conclusion: Concomitant therapy with cineole reduces exacerbations as well as dyspnea and
improves lung function and health status. This study further suggests cineole as an active controller
of airway inflammation in COPD by intervening in the pathophysiology of airway inflammation of
the mucus membrane.
Trial registration: ISRCTN07600011
Introduction
Chronic obstructive pulmonary disease (COPD) is con-
sidered to be a multi-component disease comprising
structural and functional changes inside and outside the
lungs. Effective medications for COPD are available and
can reduce or prevent symptoms, increase exercise capac-
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ity, reduce the number and severity of exacerbations and
improve health status. In common clinical use are bron-
chodilators as β-agonists, anticholinergic drugs and meth-
ylxanthines as well as glucocorticosteroids. The clinical
effectiveness of these drugs has been shown in many con-
trolled clinical studies [1-7].
Airway inflammation and mucociliary dysfunction in
COPD patients have direct clinical consequences on the
decline of lung function. As a consequence of cigarette
smoking the ciliated epithelium is damaged and the
mucus membrane becomes inflamed, resulting in
decreased mucociliary transport leading to an accumula-
tion of mucus within the airway so that the likelihood of
recurrent respiratory infection is increased. Cineole has
positive effects on the beat frequency of the cilias in the
mucus membrane and has bronchodilating and anti-
inflammatory effects. Therefore, it is appropriate to postu-
late that cineole will show positive influence on the exac-
erbations as well as on the lung function in COPD
patients – even as concomitant therapy [8-13].
We conducted a randomised, placebo-controlled multi-
center trial with the concomitant prescription of cineole –
the main constituent of eucalyptus oil – in patients with
stable COPD. The primary hypothesis was that cineole
would decrease the number, severity and duration of exac-
erbations. Secondary outcome measures were lung func-
tion, severity of dyspnea and quality of life as well as
relevant adverse effects.
Materials and methods
Enrolment of participants
Participants were recruited in the offices of 4 general prac-
titioners and 7 specialists in pneumology in Germany.
The study was carried out during the winter seasons 2003/
2004 and 2004/2005 over a treatment period of 6 months
in the winter and starting the enrolment in September at
the earliest. The participants were 40 to 80 years of age
and had airflow limitation with FEV1 of less than 70% and
more than 30% of the predicted value (moderate to severe
COPD; according to GOLD classification stages 2 and 3 of
COPD) [14]. Patients with an increase of more than 15%
and more than 200 ml in FEV1 after inhalation of β-ago-
nists (at least 200 μg Salbutamol or equivalent) were
excluded according to the definition of COPD of the Ger-
man Airway-League. [15]. All patients were current smok-
ers or ex-smokers with at least 10 pack years. Patients were
excluded if they had severe medical conditions such as
bronchial carcinoma, myocardial infarction, alcoholism,
heart failure. All randomised patients provided written
informed consent and the protocol was approved by the
local Ethics Committees at each of the 11 participating
centres.
Treatment groups
242 patients were randomly assigned to one of the two
treatment groups with stratification according to the clin-
ical centres. All patients were given the necessary dose of
capsules each containing 100 mg cineole or no active
ingredient. For each group 2 capsules 3 times daily were
prescribed resulting in a dose of 600 mg per day for the
cineole or no cineole for the placebo group as concomi-
tant therapy. Patients were instructed to take the capsules
half an hour before meal so that they could not recognize
the smell of cineole. Capsules with active substance and
placebo looked absolutely identical and were sealed in
blister stripes.
The diagnosis of COPD was confirmed according to the
current guidelines of "Global Initiative for Chronic
Obstructive Lung Disease" (GOLD). Frequency, duration,
severity and symptoms of exacerbations were defined
according to the literature [16-18]. An exacerbation was
documented when the duration was more than 3 days or
a complex of at least 2 respiratory adverse events with a
duration of more than 3 days occurred. Exacerbation
severity was defined as: mild (Score = 1, increased need for
basic medication of COPD which the individual can man-
age in its own normal environment), moderate (score = 2,
increased need for medication and he/she feels the need
to seek additional medical assistance) and severe (score =
3, patient recognise obvious and/or rapid deterioration in
conditions requiring hospitalisation). Details for the
number, duration and severity as well as treatment and
symptoms of exacerbations were recorded in the patient's
diary for each day. Since the most relevant differentiation
for exacerbations are frequency, duration and severity, the
multiple criteria were combined as primary outcome
measures for the statistical evaluation.
Secondary outcome measures were the single parameters
of the exacerbation as well as lung function, symptoms
and quality of life. Spirometric measurements were car-
ried out before the beginning of the study determining
reversibility of the airflow limitation by inhalation of
short acting β2-agonists to assure that the reversibility of
lung function was less than 200 ml or 15%. Spirometric
measurement included determination of forced expira-
tory volume in 1 second (FEV1), forced vital capacity
(FVC) and vital capacity (VC) at the beginning and after 3
and 6 months. Additionally, symptoms score were deter-
mined for dyspnea (scores: 0 = caused no problems, 1 =
caused occasionally problems, 2 = caused a lot of prob-
lems, 3 = the most important problem the patient had),
weekly frequency of dyspnea (scores: 0 = no day was good,
1 = 1–2 days were good, 2 = 3–4 days were good, 3 =
nearly every day was good, 4 = every day was good), gen-
eral conditions (scores: 0 = good, 1 = impaired, 2 = bad, 3
= very bad, 4 = unbearable), cough (scores: 0 = never, 1 =Respiratory Research 2009, 10:69 http://respiratory-research.com/content/10/1/69
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rarely, 2 = occasionally, 3 = often, 4 = very often, 5 = nearly
continuously).
Diagnosis-related quality of life was determined accord-
ing to the "St. George's Respiratory Questionnaire" [19].
Visits and Randomization
Before randomisation we ascertained the patients' eligibil-
ity and conducted spirometry. After the randomisation
the following parameters were recorded: height, weight,
age, time since first symptoms for the diagnosis of COPD,
documentation of allergies, concomitant disease, smok-
ing habits (documentation of pack years), number of
exacerbations in the year before during winter time, deter-
mination of quality of life and current maintenance ther-
apy. The following control visits were carried out after 1,
2, 3, 4, 5 and 6 months recording exacerbations since last
visit, frequency of dyspnea, characterisation of dyspnea,
hypersecretion and cough as well as adverse events, com-
pliance and change of therapy. Spirometry was carried out
at the beginning of the study as well as after 3 and 6
months of treatment. Quality of life was determined at the
beginning and at the end of the study.
Statistical analysis
The proposed sample size for the present trial was 240
patients for both treatment groups. The sample size was
chosen to detect a minimum difference of 15% of exacer-
bations after 6 months of treatment. Analysis of efficacy
was performed with the intention-to-treat-population
including all eligible patients who received at least one
dose of medication and had at least one follow-up visit.
The number of all exacerbations, duration of exacerba-
tions, degree of severity of exacerbation recorded in
patients diary during the 6 months treatment period were
summarised and the sums compared according to Wei-
Lachin's directional test of multiple criteria (equally
weighted) [20]. Additionally, single parameters character-
ising the exacerbations and dyspnea were analyzed explor-
atory as secondary outcome measures at multiple
endpoints according to Wei-Lachin validating the sum-
formation. The Wilcoxon-Mann-Whitney-U Test was used
for all other secondary outcome measures. Data are
expressed as mean values (with SD) and all tests were two-
tailed. P-values of 0.05 or less were considered to indicate
statistical significance.
Results
A total of 242 patients were randomised and received at
least one dose of study medication. 22 patients were
excluded from the statistical analysis of efficacy because
they did not meet the requirements of the GOLD guide-
lines since FEV1/VC was > 0.7. 220 patients were eligible
according to the GOLD guidelines having COPD of stage
II and III. The two treatment groups were well matched
with respect to baseline characteristics (table 1). The mean
age of the participants at entry was 62 years in both
groups. The mean duration of COPD of 13 years as well as
31 pack-years and the basic medication (i.e. ICS, β-ago-
nists, anticholinergics and theophylline) were balanced
between the two groups (table 2). Medication was not
changed during the treatment period except in occurrence
of exacerbations. The baseline lung function and reversi-
bility in both groups were comparable. Treatment compli-
ance was determined by counting the study medication at
each visit and was found high and comparable across the
treatment groups.
Primary outcome measures
Exacerbations
At baseline the mean exacerbation rate was 3.2 in both
groups during the previous year. The number of patients
with exacerbations during the treatment period in the cin-
eole group was 31 patients (28.2%) and 50 patients
(45.5%) in the placebo group. As primary outcome meas-
ure the sum of exacerbations for frequency, duration and
severity at all 6 following visits as composite endpoint
(equally weighted) were calculated according to the Wei-
Lachin Test procedure for multiple criteria and showed a
statistically significant difference for the primary outcome
measure between both treatment groups (p = 0.0120)
Table 3. Calculating these single parameters alone explor-
atory according to Mann-Whitney-U it could be proven
that they were statistically significant too (i.e. for fre-
quency 0.0069 an, duration 0.0210 and for severity
0.0240). Validating these results by Wei-Lachin-Test pro-
cedure for multiple endpoints for the number, the degree
and the severity of exacerbations, the degree during the 6-
month treatment the differences between both treatment
groups were statistically significant (p = 0.0016, 0.0031
and 0.0025) which underlines higher sensitivity of this
test-procedure. Medication of the exacerbations with
additionally applied corticosteroids occurred in 17 cases
in the cineole and in 25 cases in the placebo group which
was not statistically significant different.
Secondary outcome measures
Lung function
Patients only discontinued inhaled β2-agonist prior to
spirometry testing. After inhalation of a β2-agonist the
reversibility of lung obstruction (increase of FEV1) at the
start of the study was 4.5% in the cineole group and 5.5%
in the placebo group (table 1). After 6 months of treat-
ment the mean FEV1 increased by 78 ml (4.7%) in the cin-
eole group (table 4). The mean differences between both
groups were not statistically significant (p = 0.0627). After
6 months of treatment an increase of FVC by 62 ml
(2.7%) after cineole therapy and a decline of 25 ml
(1.1%) after treatment with placebo was determined. TheRespiratory Research 2009, 10:69 http://respiratory-research.com/content/10/1/69
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difference concerning change of FVC and VC between
both treatment groups was not clinically relevant.
Dyspnea
The differences between both groups after 6 months of
treatment are summarised in table 4. The baseline dysp-
nea scores in the morning, trouble in breathing, dyspnea
at rest and dyspnea during exercise were similar in both
groups, indicating a moderate level of a dyspnea for most
patients at the beginning of the treatment period. Calcu-
lating the values at all 6 visits at multiple endpoints the
difference between both treatment groups were statisti-
cally significant for trouble in breathing, dyspnea in the
morning and dyspnea at rest. Dyspnea during exercise did
not show a statistically significant difference between
treatment groups.
Quality of life
At 6 months the mean improvement of SGRQ total symp-
tom score was -9.1 after treatment with cineole and -4.1
after treatment with placebo (table 5). The difference
between treatment groups was not statistically significant
(p = 0.0630). The improvement of the symptom score was
statistically significant (p = 0.0224). The differences of
changes of activity score and impact score were not statis-
tically significant between the two groups.
Multiple criteria
Symptomatic of COPD patients is characterized by lung
function, dyspnea and quality of life. In order to include
Table 1: Base Line Characteristics of the Patients*
CHARACTERISTIC PLACEBO
(N = 110)
CINEOLE
(N = 110)
Age – yr
Mean 62.5 ± 10.2 62.2 ± 9.1
Range 40 – 79 41 – 79
Sex – M/F 75/35 66/44
Weight – kg
Mean 79 ± 16 79 ± 14
Range 48 – 120 52 – 113
Height – m
Mean 1.71 ± 8.8 1.70 ± 8.0
Range 1.48 – 1.90 1.54 – 1.92
Years since appearance of COPD
Mean 12.8 ± 9.7 13.6 ± 10.9
Range 1 – 56 1 – 59
Severity of COPD [number of patients]
Moderate COPD (II) 69 68
Severe COPD (III) 41 42
FEV1/VC [%] 58.0 58.7
FEV1 [l] 1.61 ± 0.5 1.62 ± 0.5
FEV1 % predicted value 54.4 54.9
Reversibility (increase of FEV1 after inhalation of β-agonist) [%] 5.5 4.5
Allergies (number) 10 9
Pack years 31.5 ± 19 31.3 ± 16
* Plus – minus values are means ± SD.
Table 2: Constant concomitant therapy
THERAPY PLACEBO
(N = 110)
CINEOLE
(N = 110)
Inhaled β-agonists* (LABA and SABA) 83 88
Inhaled anticholinergics 29 35
Inhaled corticosteroids (ICS) 27 25
Theophylline 38 32
* including combinationsRespiratory Research 2009, 10:69 http://respiratory-research.com/content/10/1/69
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these relevant secondary outcome measures together we
used these parameters equally weighted as multiple crite-
ria. The increase of FEV1, amelioration of dyspnea and
improvement of total score of "SGRQ" were calculated
according to the Wei-Lachin Test procedure for multiple
criteria and showed a statistically significant difference for
the relevant secondary outcome measure between both
treatment groups (p = 0.0024).
Other findings
Concomitant therapy with β-agonists and anticholiner-
gics, corticosteroids or combinations and methylxan-
thines in both groups were comparable (table 2). The
global assessment of efficacy showed a significant differ-
ence, which correlated with the amelioration of clinical
findings after treatment with cineole.
Side effects
All patients receiving the study medication (including
those with FEV1/VC > 0.7) were included in the safety
examination. During treatment side effects were seen in
22 patients whereas in 17 cases adverse events were not
related to the study medication. In the placebo group 11
adverse events were estimated not being related to the
study medication whereas 2 cases were interpreted as
being related to the study medication (heartburn). During
treatment with cineole 9 cases of adverse events were
reported whereas 6 adverse events were reported not being
related to the study medication. In 3 patients (nausea,
diarrhoea, heartburn) the adverse events were estimated
being related to the study medication. The difference
between the two treatment groups was neither clinically
relevant nor statistically significant. Safety examinations
of the global assessment showed no difference between
the two treatment groups. During the 6 months of treat-
ment compliance was good in all patients.
Discussion
Patients with COPD experience exertional breathlessness
caused by bronchoconstriction, mucous secretion, edema
of the airway wall and loss of attachments to the terminal
airways [14]. Hence pharmacological therapy has focused
on the treatment of airway obstruction and inflammation
to improve symptoms primarily dyspnea as well as health
status. Bronchodilators are the mainstay of pharmaco-
therapy for patients with COPD. On the other hand it is
well known that mucociliary dysfunction has direct clini-
cal implications. Mucus is beneficial in normal quantities
Table 3: Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*
PLACEBO CINEOLE
SCORE SCORE P VALUE†
Sum of exacerbations (number)# 0.9 ± 1.46 0.4 ± 0.82 0.0069
Sum of duration (days)# 5.7 ± 8.9 4.0 ± 10.9 0.0210
Sum of severity (score)# 1.4 ± 2.2 0.8 ± 1.5 0.0242
Summarized parameter
(directional test)
0.0120
* Plus – minus values are means ± SD.
† P-Values are for the comparison between the two groups.
# The sum of the exacerbation parameters is calculated by addition of the documented parameters at all visits.
Table 4: Secondary outcome measures during 6 months Of treatment with cineole or placebo for change of lung function and dyspnea 
symptoms *
LUNG FUNCTION AND SYMPTOMS PLACEBO CINEOLE
BASE LINE 3 MONTHS 6 MONTHS BASE LINE 3 MONTHS 6 MONTHS p-Value
FEV 1 [l] 1.61 ± 0.5 1.62 ± 0.5 1.61 ± 0.5 1.62 ± 0.5 1.67 ± 0.5 1.70 ± 0.6 0.0627†
FVC [l] 2.23 ± 0.8 2.25 ± 0.8 2.22 ± 0.7 2.33 ± 0.8 2.36 ± 0.9 2.36 ± 0.9 0.2409†
VC [l] 2.81 ± 0.8 2.71 ± 0.7 2.68 ± 0.8 2.80 ± 0.8 2.73 ± 0.8 2.72 ± 0.9 0.2060†
Trouble in breathing # 1.8 ± 0.9 2.1 ± 0.9 2.2 ± 1.0 1.9 ± 0.9 2.4 ± 1.0 2.5 ± 1.1 0.0103&
Dyspnea in the morning $ 1.1 ± 0.7 0.9 ± 0.7 0.7 ± 0.7 1.1 ± 0.8 0.7 ± 0.7 0.5 ± 0.6 0.0466&
Dyspnea at rest $ 0.7 ± 0.7 0.4 ± 0.6 0.4 ± 0.6 0.6 ± 0.6 0.3 ± 0.5 0.3 ± 0.5 0.0156&
Dyspnea during exercise $ 2.0 ± 0.6 1.8 ± 0.7 1.7 ± 0.8 2.0 ± 0.6 1.7 ± 0.7 1.5 ± 0.9 0.1252&
* Plus – minus values are means ± SD. Higher scores on the symptoms-sum-score indicate more disease activity.
† P-Values are for the comparison of the changes from base line to 6 months between the two groups.
&P-Values for the comparison are calculated by the multiple criteria calculation of 6 visits by Wei-Lachin between the two groups.
# Scores: 0 = no day was good, 1 = 1–3 days were good, 2 = nearly every day was good, 3 = every day was good in a week.
$ Scores: 0 = did not cause any problems, 1 = sometimes caused problems, 2 = caused a lot of problems, 3 = the most important problem the 
patient hadRespiratory Research 2009, 10:69 http://respiratory-research.com/content/10/1/69
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but in case of mucus hypersecretion when cilia fail, the
mucus pool allows bacterial colonisation. The presence of
pooled bacteria results in the release of bacterially-derived
toxins that destroy the underlying epithelium and trigger
a neutrophilic response [21]. Taking into account the
known pharmacological effects of the defined natural
product cineole it was assumed that this compound might
be beneficial for patients with COPD.
Exacerbations have been shown to be reduced in various
studies evaluating treatment with inhaled β-agonists or
corticosteroids or combinations. The major finding of the
present study is that cineole provides a significantly
greater reduction of frequency, duration and severity of
exacerbations than placebo. The exacerbations were ana-
lyzed as multiple criteria for the relevant specifications fre-
quency, duration and severity. The result for the primary
outcome measure could be validated exploratory for the
single parameters showing a statistical significant differ-
ence too. Therefore, both testing procedures are valid
whereas the testing multiple criteria is more sensitive. This
proof of efficacy is an important contribution to the
known pharmacological properties of cineole which
therefore is not a mucolytic agent only. The result of this
study suggests important new evidence of superior thera-
peutic efficacy of additional therapy with cineole to better
control COPD exacerbations compared to the currently
recommended combined therapy with ICS and LABA.
Furthermore, additional therapy with cineole may posi-
tively interact with anti-inflammatory activity of recom-
mended airway therapies in COPD and may serve to
protect airways from other environmental agents.
In general, quality of life deteriorates slowly in patients
with COPD. During the period of 6 months treatment of
this study we observed a decrease of the scores of SGRQ in
both treatment groups. The reason for this finding in the
placebo group, too, seems to be due to patients receiving
better medical attention when involved in clinical trials.
The higher rate of exacerbations in the winter before the
study began in both treatment groups is due to the same
reason. Our present data with cineole therapy underline a
greater improvement than after treatment with placebo.
Differences in change of FEV1 were not statistically signif-
icant (p = 0.0627). These findings correlate with a decline
of FEV1 in the placebo group of 0.4% and an increase of
4.8% in the cineole group. This value is nearly identical
with the increase of FEV1 after the inhalation of β-ago-
nists, when testing the reversibility, before concomitant
therapy with cineole started for six months.
Conclusion
These collective findings underline that cineole not only
reduces exacerbation rate but also provides clinical bene-
fits as manifested by improved airflow obstruction,
reduced severity of dyspnea and improvement of health
status. Therefore, cineole can provide a useful treatment
option for symptomatic patients with COPD in addition
to treatment according to the guidelines. These results
have to be seen in context with socio-economic aspects. As
COPD is an extremely costly disease and a cause of major
financial and social burden concomitant therapy with cin-
eole can be recommended, especially due to the lack of
relevant side effects and relatively low cost. The results of
our study provide good evidence that cineole will show
benefits as additional therapeutic regimen in patients
with COPD. These findings correspond to the interpreta-
tion of the efficacy-study with Carbocysteine but not with
Acetylcysteine, because this medication did not show a
significant reduction of exacerbations [22,23].
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Table 5: Secondary outcome measures for saint george's respiratory questionnaire (sgrq): Change of total symptom score, symptom 
score, activity score and impact score During 6 months of treatment with cineole or placebo*
SGRQ SCORES PLACEBO CINEOLE P VALUE †
BASE LINE 6 MONTHS BASE LINE 6 MONTHS
Symptom score 57.4 ± 20.2 48.5 ± 24.9 57.3 ± 20.4 43.8 ± 24.3 0.0224
Activity score 53.4 ± 21.9 50.0 ± 24.8 52.1 ± 20.5 43.5 ± 22.4 0.2032
Impact score 37.2 ± 20.9 33.9 ± 23.3 35.8 ± 20.2 27.4 ± 19.2 0.1126
TOTAL SYMPTOM SCORE 45.6 ± 18.9 41.3 ± 22.5 44.4 ± 17.8 34.5 ± 18.9 0.0630
* Plus – minus values are means ± SD. Lower scores on the scores indicate higher quality of life.
† P-Values are for the comparison of the changes in scores from base line to 6 months treatment between the two groups.Publish with BioMed Central    and   every 
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